Article

Phase III trial uses innovative delivery system to treat DME

Alimera Sciences Inc. and Control Delivery Systems Inc. (CDS) began a phase III clinical trial to study patients with diabetic macular edema (DME) treated using the Medidur implant to deliver fluocinolone acetonide.

The masked, randomized, multicenter study will follow 900 patients in the United States and Europe for 36 months. The Medidur implant, injected through a needle during an in-office procedure, is expected to provide sustained delivery of fluocinolone acetonide to the back of the eye for up to 3 years, according to Alimera Sciences.

"Advanced therapies require innovative methods of delivery, and Medidur fits that model," said Dan Myers, president and chief executive officer of Alimera Sciences, Alpharetta, GA. "The Alimera Sciences team is delighted to reach this critical product development milestone with CDS at such a stage of our company's progression. We anticipate that Medidur technology will allow eye-care professionals to provide their DME patients with an effective and long-lasting therapeutic treatment."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.